header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

THROMBOPROPHYLAXIS IN PATIENTS UNDERGOING HIP REPLACEMENT: A SURVEY OF BRITISH ORTHOPAEDIC SURGEONS



Abstract

Venous thrombo-embolism is a common complication following hip replacement. The recently-published pulmonary embolism prevention study reported that aspirin decreased the fatal pulmonary embolism rate in patients with femoral neck fractures. In addition, new products (synthetic factor X-inhibitor Fondaparinux and direct thrombin-inhibiter Desirudin) have been reported to be more effective than low-molecular-weight heparin in preventing asymptomatic DVT. We thought it important to update the 1997 survey on thrombo-embolism prophylaxis by British Orthopaedic Surgeons.

A single page questionnaire was sent to 1308 members of the British Orthopaedic Association who are consultant orthopaedic surgeons. Those who did not respond received a reminder. We had a 72% response rate.

All surgeons use some form of prophylaxis, with 85% using pharmacological agents. Low-molecular-weight heparin is used by 55% of surgeons, while 20% use only aspirin. Fewer than 1% (five consultants) use early mobilisation and nearly 2% (13 consultants) use graded stockings and early mobilisation as their only prophylactic measures. Unit policies govern 74% of surgeons. In the last 3 years, 30% have changed their regime.

Most British orthopaedic surgeons still use pharmacological thromboprophylaxis. The use of aspirin has increased from 5% to 30%. Aspirin is often combined with a mechanical prophylactic. The use of intermittent calf compression has increased from 3% to 22% and of foot pumps from 12% to 19%. The use of low-molecular-weight heparin has fallen by 10%.

Secretary: Dr H.J.S. Colyn, Editor: Professor M.B.E. Sweet. Correspondence should be addressed to SAOA, Box 47363, Parklands, Johannesburg, 2121, South Africa.